New stock news | Kinhow Pharmaceutical's Hong Kong IPO prospectus has become ineffective.

According to the Wise Finance and Economics APP, the Hong Kong stock prospectus submitted by Qinhao Pharmaceuticals (Suzhou) Co., Ltd. (referred to as Qinhao Pharmaceuticals) on January 16, 2026 expired after 6 months on July 16, 2026, with Huatai International as its exclusive sponsor.